logo
Exclusive: Military contractor says she was fired for noting problem that ‘jeopardized the safety of U.S civilians and troops'

Exclusive: Military contractor says she was fired for noting problem that ‘jeopardized the safety of U.S civilians and troops'

Yahoo17-07-2025
A software engineer working for one of the Pentagon's most prominent defense contractors claims she was fired after flagging 'critical software safety issues and errors' written into the code that controls high-tech automated artillery systems used by U.S. forces, as well as various other nations throughout the world.
Deborah Hale alleges the problems violated at least eight different laws, rules, or regulations set out by the Army, Department of Defense, NATO and even NASA, which 'would have prevented appropriate safety tests from being properly developed and tested, severely jeopardizing the safety of American civilians, troops, and allies,' according to a state lawsuit that has now been removed to federal court.
Hale's suit says that since she was let go in 2023, the Reston, Virginia-based Science Applications International Corporation – known as SAIC, Inc. – has blackballed her throughout the industry.
SAIC has annual revenues of some $7.5 billion, and works extensively with the federal government across numerous agencies, in addition to the DOD.
Attorney Kelly Chanfrau, who is representing Hale, called her client 'an incredible employee with vast knowledge and experience.'
'Her allegations and complaints are serious and no employee should be retaliated against based upon complaints, especially when she was trying to protect our military and civilians,' Chanfrau told The Independent.
In an email, an SAIC spokesperson said, 'SAIC cannot comment on any litigation matters.'
The software underpinning the U.S. military's Multiple Launch Rocket System, or, MLRS, contained crucial errors, according to a whistleblower lawsuit. The software underpinning the U.S. military's Multiple Launch Rocket System, or, MLRS, contained crucial errors, according to whistleblower Deborah Hale's lawsuit (U.S. Army photo by KCpl. Siwon Koo, 2nd Infantry/ROK-U.S. Combined Division Public Affairs)
Hale has worked as a software safety engineer since 1983, at defense giants such as BAE Systems, Lockheed Martin and Northrop Grumman. A Subject Matter Expert in system safety of military weapons, SAIC hired Hale in September 2022, as a software safety engineer, her complaint states.
On April 1, 2023, Hale was promoted to system safety manager, which came with a salary increase from $175,000 to $180,000, and 'required [her] to conduct a line-by-line review of the software code' underpinning the Multiple Launch Rocket System, or, MLRS, an automated surface-to-surface rocket artillery platform, according to the complaint.
Among other things, the MLRS software is used to calculate missile trajectories based on targeting information human operators type into the system, military analyst Dan Grazier, who served as an officer in the U.S. Marine Corps and is now at the nonprofit Stimson Center, told The Independent.
In addition to the U.S. military, precision-fire MLRS systems are a key part of various European arsenals, along with Egypt, South Korea, and Norway, and have seen action in Iraq, Ukraine and beyond.
Shortly after beginning the code review, Hale discovered 'several' serious problems with it that could put U.S. and allied troops in harm's way, the complaint contends.
'The issues and errors were in violation of the following laws, rules, and regulations, including, but not limited to: the Department of the Army and United States Army Aviation and Missile Command AMCOM Regulation 385-17 Software System Safety Policy, the Defense Acquisition System, the United States Army Safety Program, the Department of Defense Standard Practice for System Safety, Joint Services Safety Authorities, Missile Defense Agency Assurance Provisions, NASA-GB-1740.13, and North Atlantic Treaty Organization Allied Ordinance Publication 52,' the complaint goes on.
Deborah Hale says the problems she brought up concerning the MLRS missile system could have put American civilians, troops, and allies in harm's way, but that she was ignored by her supervisors at defense contractor SAIC (PAUL J. RICHARDS/AFP via Getty Images)
Although court filings do not list the specific aspects the code allegedly violated, AMCOM Regulation 385-17, for example, says '[s]oftware defects affecting safety-critical functions are causes of system level hazards, such as unplanned missile launch,' and that 'near-misses' have occurred 'as a result of software defects or inadequate specification of software system safety requirements.'
Hale promptly notified her bosses about her findings, according to the complaint. However, it maintains, 'Instead of taking action to correct the code and ensure the code was safe, [SAIC] ignored [Hale's] reports, and nothing was done.'
A week later, Hale raised the issue again, bringing her concerns to a different manager at SAIC, the complaint continues. This manager, it says, looped in two higher-level managers 'due to the seriousness of the issue.'
But a few days after that, Hale was suddenly informed by her supervisor that she was being removed from the MLRS project and would be reassigned to another team, the complaint states.
On April 13, 2023, before the transfer had a chance to occur, Hale spoke up at a staff meeting, appealing to higher-ups about the issues and errors she said were baked into the MLRS project's code, according to the complaint. A senior safety engineer corroborated Hale's findings, it says. In response, Hale's boss reiterated that the MLRS program 'would be moving forward without her,' the complaint alleges.
The next day, Hale was placed on unpaid leave, and told that she had until May 12 to find another job at SAIC or she would be terminated, according to the complaint.
'To no surprise to [Hale], she could not secure another position with [SAIC] due to her complaints of violations, rules, and regulations compromising safety,' the complaint states.
It says that by making it impossible for Hale to transfer internally, she was 'effectively terminated' on April 14.
Since then, SAIC 'has continued to retaliate against [Hale] by making it difficult for her to find subsequent employment,' according to the complaint.
Hale's 'allegations and complaints are serious and no employee should be retaliated against based upon complaints, especially when she was trying to protect our military and civilians,' her attorney Kelly Chanfrau told The Independent (75th Field Artillery Brigade/U.S. Army photo by Sgt. Christian Carrillo)
'The whistleblower angle of this story is all-too-common unfortunately,' Grazier told The Independent. 'I've seen this a few times, when earnest people identify a problem and try to deal with it through the appropriate channels only to see their concerns ignored and receive a termination notice as a reward for trying to do the right thing.'
Had everyone on Hale's team had simply listened to her and dealt with things, the outcome, across the board, would have been far better, according to Grazier.
'But for some odd reason, it happens this way far too often,' he said.
It is unclear if the issues that Hale flagged have since been addressed. An Army spokesperson told The Independent that it 'does not comment on ongoing litigation.'
Contrary to SAIC's apparent distaste for Hale, she has received glowing recommendations on LinkedIn from former managers.
'Deborah is the single smartest woman with whom I have ever worked in systems safety,' one wrote. 'Her high level of professionalism ending with products exceeding expectations make her a valuable asset to any organization.'
Another said: 'I was Deborah's manager when she transferred into System Safety, an engineering discipline that usually takes years to become effective; she grasped the concepts and was producing within months… Deb is definitely a team player[,] always ready to assist others and ensures the final product achieves the customer's expectations.'
Hale's lawsuit says her firing from SAIC led to emotional distress and humiliation.
She is seeking back pay and benefits, front pay, compensatory damages, emotional distress damages, punitive damages, attorneys' fees and court costs and reinstatement to her former position.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The 3 Things That Matter for CRISPR Therapeutics Now
The 3 Things That Matter for CRISPR Therapeutics Now

Yahoo

time12 minutes ago

  • Yahoo

The 3 Things That Matter for CRISPR Therapeutics Now

Key Points CRISPR Therapeutics' gene-editing treatments are highly customized and shockingly expensive. The market is watching to see if the underlying science can be applied to treat many diseases. The company has plenty of money right now, but its expenses could grow quite a bit from here. 10 stocks we like better than CRISPR Therapeutics › Biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP) isn't a name on many investors' radar -- and understandably so. Its market capitalization is a mere $6 billion. The company remains in the red largely because it's barely got any revenue to speak of. It's not likely to swing to a profit in the immediate future, either. Still, if you've got room in your portfolio for a little more risk paired with above-average upside potential, this is a stock worth adding to your watchlist (if not your portfolio) with three key things in mind. But first things first. What's CRISPR Therapeutics? Although the company was founded back in 2013, most of its time since then has been spent refining the work first done by Jennifer Doudna, Ph.D., and co-founder Emmanuelle Charpentier, Ph.D., who jointly figured out how to "edit" defective genetic code in a strand of DNA. By using a protein called Cas9 to find and remove a damaged portion of a genetic sequence and then replace it using a gene-editing biotechnology based on clustered regularly interspaced short palindromic repeats -- or CRISPR -- medical science is now able to do what was once unthinkable. It's still early days for the science -- very early. In fact, the FDA only made its first-ever approval of a gene-editing therapy in December of 2023. That's Casgevy, for the treatment of sickle cell disease, which was approved in the U.K. only a month earlier. The thing is, Casgevy is CRISPR Therapeutics' treatment, underscoring how well developed this biotech outfit's science is, and perhaps indirectly underscoring the fact that many rival drug developers are still well behind. Casgevy isn't the company's proverbial big Kahuna, however -- it's merely proof that gene editing can be successfully done. The heavy hitters in CRISPR's developmental pipeline are CTX310 for the treatment of certain cardiovascular diseases, and CTX131 and CTX112, both of which are taking aim at cancer using the very same CRISPR science. Although all of these drugs still have years of developmental work ahead of them, again, the underlying gene-editing technology works. Its potential applications are enormous. That's why CRISPR has a dozen or so others in clinical or pre-clinical trials also underway at this time. Three things to watch As time marches on, though, this stock's backstory is evolving from one broadly driven by an idea to one that increasingly hinges on some very specific factors. To this end, here are the three things that matter the most to current and prospective CRISPR Therapeutics shareholders right now -- and for the foreseeable future -- since they'll either drive the stock higher or let it slide into a sell-off. 1. Insurers and patients' acceptance of CRISPR-based medicine's cost While the science of using CRISPR to repair faulty cells is exciting, it's not exactly cheap or easy. See, Casgevy isn't a pill or an injection. It requires a sample of a patient's own blood stem cells to create a completely customized therapy, which is then infused back into that patient after he or she has undergone chemotherapy. All of this care can only be done at one of CRISPR's 65 authorized treatment centers. Total cost? A little over $2 million per patient. That's pretty steep for any therapy, but particularly for sickle cell disease, which at least has a handful of more affordable treatment options. The cost of treating life-threatening cancer is less of a stumbling block, even for insurers that may occasionally see bills nearly this size for even the most conventional of oncology treatment regimens. The price tag of this and any other future CRISPR-based therapy, however, is likely to remain in this ballpark, where payers may well balk. 2. The ongoing development of CTX310 Again, while Casgevy is approved to treat sickle cell disease, it's really more of a proving ground for the other drugs in CRISPR Therapeutics' developmental pipeline. This, of course, includes CTX131 and CTX112, but the company itself is putting the spotlight on CTX310 as a treatment for ANGPTL3 (angiopoietin-like 3), which is often associated with poorly regulated cholesterol, lipids, and triglycerides. If the company can demonstrate its solution is at least as good as (if not better than) alternative cholesterol-fighting drugs, investors might continue to support this stock. This information is coming. The company posted encouraging early results of CTX310's phase 1 clinical trial late last month, and says it intends to offer more detailed data at a healthcare conference scheduled for later in the year. If it's compelling enough, it could tamp down worries over the high cost of any CRISPR-based treatment. 3. Liquidity Finally, you'll want to keep an eye on CRISPR Therapeutics' liquidity, or the amount of cash it has on hand to cover its operating costs while it continues to develop CTX310 at the same time it's looking to expand Casgevy's commercialization. As of the end of the first quarter, CRISPR was sitting on $1.86 billion in cash, which is a lot for a company of this size. It's working through this money pretty quickly, though, shelling out nearly $150 million in operating expenses in Q1 alone. That doesn't include a full quarter's worth of the sort of costs the phase 1 trial of CTX310 is incurring now, or any other trials it starts or expands in the foreseeable future. Continued revenue growth from Casgevy should seemingly help offset some of this spending, even if not all of it. Indeed, the analyst community expects CRISPR's top line to soar from less than $50 million this year to more than $400 million in 2027, even if these same analysts believe the company will still be well in the red then. A few years' worth of losses isn't exactly unusual for a young biotech start-up. CRISPR Therapeutics would still lack much-needed scale even after such growth, though. The money it needs to spend just to get any meaningful degree of traction from Casgevy or maintain its clinical trials could far exceed any conceivable amount of revenue the newly approved drug might produce in the foreseeable future. Don't confuse what CRSP stock is So what's the call? There isn't one -- not this time. Buying or avoiding a stake in CRISPR Therapeutics is entirely up to you, depending on your risk tolerances and your ability to manage such a holding. If you're strictly a buy-and-hold investor, there's probably not enough certainty here yet to latch onto for the long haul. And there may never be. If you've got a speculative side that can tolerate risk in exchange for hype-driven reward, though, you could make a decent bullish case. Just don't confuse the two, or muddy the waters by trying to be both. The last thing you want to do here is talk yourself into a long-term position that requires you to ignore obvious red flags like the three potential ones discussed above. Should you buy stock in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool has a disclosure policy. The 3 Things That Matter for CRISPR Therapeutics Now was originally published by The Motley Fool

‘Cleared for Takeoff': Truist Suggests 2 Aerospace Stocks to Buy Ahead of Earnings
‘Cleared for Takeoff': Truist Suggests 2 Aerospace Stocks to Buy Ahead of Earnings

Yahoo

time12 minutes ago

  • Yahoo

‘Cleared for Takeoff': Truist Suggests 2 Aerospace Stocks to Buy Ahead of Earnings

Earnings season is in full swing, and investors are on the hunt for opportunities. One place where optimism is building – both on Wall Street and across the tarmac – is the aerospace sector. With commercial air travel rebounding and defense spending holding steady, several industry players appear well-positioned to deliver strong quarterly results. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Reinforcing this upbeat outlook, Truist analyst and aerospace expert Michael Ciarmoli believes investors should buckle up and prepare for takeoff. The analyst sees promising momentum in small- to mid-sized aerospace names ahead of their earnings reports. He highlights encouraging data points, such as year-over-year delivery increases from Boeing and Airbus – the world's leading aircraft manufacturers – as well as continued robust demand from the U.S. Department of Defense. 'Heading into 2Q25 earnings season we generally have a positive view of the demand backdrop across all A&D sub-sectors — comm'l aero aftermarket, comm'l aero OEM, and defense… We believe quarterly results will be solid and firmly anticipate that 2025 outlooks can be lifted. Our degree of confidence is highest in the aero aftermarket followed closely by aero OEM which seems poised to benefit from higher MAX and LEAP rates in the coming months,' Ciarmoli noted. With that setup, Ciarmoli has his eye on two small-cap aerospace stocks he believes are especially well-positioned heading into earnings. A quick scan through the TipRanks database shows that these are still flying under the radar, with Ciarmoli among the few analysts covering them. Let's dive in and see what makes these compelling choices. Astronics Corporation (ATRO) First up is Astronics, a $1.2 billion aerospace tech player that's been quietly powering the skies since 1968. Known for pushing the envelope on innovation, the company has carved out a strong niche in advanced support systems for commercial, business, and military aircraft. From cockpit lighting to power distribution and connectivity solutions, Astronics is embedded in the high-tech backbone of modern aviation. Its expertise shines, literally, in the cockpit, where it supplies lighting systems for instrument panels, as well as illumination for cabins and aircraft exteriors. The company also delivers integrated electrical power systems, including those tucked into passenger seating. Along with the lighting and power systems, Astronics provides products and solutions for connectivity and data systems, an increasingly important niche in the aircraft industry. Data systems allow aircraft cockpits to link with commercial and military applications; 'smart' sensing systems provide the information that data systems require; in-flight entertainment and connectivity are becoming ever more important for commercial carriers; and all of these are tied together by integrated engineering for turnkey solutions. Astronics backs up all its work with solutions for aircraft safety systems, ranging from onboard safety and survival kits to enhanced vision systems that allow flight crews to navigate in all conditions. Astronics works with customers across the civilian and military aviation sectors, and is known as a provider of unique or specialty technology products in various experimental aircraft programs. In a recent example, the company has been named as the supplier of the frequency converter unit for the NASA–Boeing X-66 experimental demonstrator airliner. We'll see Astronics' second-quarter results on August 6, but for now we can look back at the Q1 results. In the first quarter of this year, Astronics reported total sales revenue of $205.9 million. This was up more than 11% year-over-year, and it beat the forecast by $14 million. Sales in the key aerospace segment were up 17% y/y and hit a record level of $191.4 million. At the bottom line, Astronics had an EPS of $0.26, based on quarterly net income of $9.5 million. Looking ahead, Astronics finished the first quarter with a record-level work backlog of $673 million. Turning to Truist's Michael Ciarmoli, we find the analyst upbeat on this stock, noting that the company will see additional business as Boeing recovers from its own woes and increases production of the 737 MAX airliner series. 'We view ATRO as a beneficiary of ramping MAX production and see total MAX annual revenues tracking to 8-10% of total revenues in the 26/27 time period. We expect management will be in position to maintain its current 2025 revenue outlook of $820-$860M which contemplates potential downside pressures from tariffs and related uncertainty. While we have not made any changes to our model we believe we have seen enough tangible evidence in recent commercial aero bookings, top line revenue growth, and importantly aerospace segment margins that we believe this financial performance will continue for the remainder of 2025 and into 2026. With a higher degree of confidence in our margin and growth assumptions we believe ATRO's sharply discounted,' Ciarmoli opined. Ciarmoli puts a Buy rating on this stock, backing that with a $49 price target that indicates potential for a 42% upside in the coming months. (To watch Ciarmoli's track record, click here) You can file the stock firmly in the 'under the radar' camp, as Ciarmoli aside, there are currently no other analysts covering this name. (See ATRO stock forecast) TAT Technologies (TATT) The second Truist pick we're looking at is TAT Technologies, a smaller player with a $420 million market cap. TAT has a global footprint, and is a provider of critical systems like thermal controls, APUs, and landing gear for a wide range of aircraft platforms. Among TAT's key product lines are its thermal solutions. This is a vital area for aircraft technology; at high speeds and altitudes, aircraft encounter extremes of both heat and cold. TAT's industry-leading thermal solutions include high-temperature-resistant precoolers, fuel-submerged hydraulic heat exchangers, oil coolers, advanced cold plates, air cycle and vapor cycle ECS heat exchangers, power electronics cooling systems, and environmental control systems. These systems regulate temperature across the aircraft, from the fuel system to passenger accommodations. Also vital to the industry is TAT's expertise in APU MRO – the maintenance, repair, and overhaul of auxiliary power units. These APUs are found in most aircraft, and are used to provide power for systems other than propulsion. In commercial airliners, the APU is usually located in the tailcone and is used to provide power for cabin electricity and lighting, and for the aircraft's communication systems. TAT is also a leading provider of MRO facility for Embraer landing gear. Embraer is one of the world's largest makers of commercial airliners, after Airbus and Boeing, and specializes in medium-haul, narrow-body jets. TAT's expertise in Embraer landing gear systems is in high demand. The company also operates at the leading edge of aerospace technology. TAT is involved in eVTOL projects – electric vertical take-off and landing – a new tech that promises to bring a sea-change to short-range and urban air transport. Closely linked to this is TAT's work with hybrid electric aircraft and universal cooling systems. So, TAT has its fingers in many areas of the aerospace realm. That brought the company $42.1 million in revenue during 1Q25, a total that was up 23% from the prior-year period although it missed the forecast by $452,000. TAT's bottom line in the quarter came to 34 cents per share, beating expectations by 4 cents per share. For Ciarmoli, the future looks bright for this aerospace firm. The analyst notes a strong market for APU expertise, and writes of TATT, 'We expect favorable aftermarket trends coupled with recent APU share gains to continue to drive revenue growth. We model for 22% YOY growth in 2Q25 and 6 % seq'l growth. We would expect to see gross margins expand YOY on volume/mix and operating efficiencies and we anticipate a B2B >1x. Following the equity offering at the end of May we will look for updates from mgmt regarding use of proceeds and suspect some near term build of working capital to support the narrow body APU opportunity.' These comments support the analyst's Buy rating on TATT shares, and his $35 price target suggests a 9% upside potential in the next 12 months. While there are only 3 recent analyst reviews on record for TATT, they are all Buys, giving the stock its Strong Buy consensus rating. The shares have a current trading price of $32 and an average target price of $36 points toward a one-year gain of 12%. (See TATT stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Corsair's Elgato Launches Facecam 4K; Groundbreaking Solution Mainstreams 4K60 Video
Corsair's Elgato Launches Facecam 4K; Groundbreaking Solution Mainstreams 4K60 Video

Yahoo

time12 minutes ago

  • Yahoo

Corsair's Elgato Launches Facecam 4K; Groundbreaking Solution Mainstreams 4K60 Video

MILPITAS, Calif., July 29, 2025--(BUSINESS WIRE)--CORSAIR® (Nasdaq: CRSR) subsidiary Elgato, a global leader in content creator technology, today launched Facecam 4K, a groundbreaking studio webcam that brings DSLR-level 4K60 video to mainstream creators. Designed with a professional imaging pipeline, including a SONY STARVIS 2 sensor, advanced image processor, and Elgato's Camera Hub software, Facecam 4K delivers ultra-smooth, uncompressed Ultra HD footage with cinematic flexibility. It's also the first webcam to support 49-mm lens filters, enabling popular pro-style effects like starbursts and diffusion. Facecam 4K is available now, representing a major innovative leap in webcam technology, making broadcast-quality video and professional creative control more accessible than ever. With results rivaling many professional cameras, Facecam 4K proves that incredible video no longer requires a prohibitively expensive setup. Thi La, Chief Executive Officer of Corsair, said, "Facecam 4K is a great example of how Elgato continues to lead in creator technology, delivering pro-level 4K60 quality without the usual cost or complexity. As the creator economy evolves, we see opportunities to expand what a streaming webcam can do, especially through software, filters, and deeper app integrations. We're excited to give creators the tools they need to enhance their brand image, and this is just one step in our broader plan to drive further innovation." Customers can order Facecam 4K starting today on and at authorized retailers in CORSAIR's global network. Webpages Learn more about Facecam 4K: Get high-resolution product images: Get the Camera Hub app: About Elgato Elgato is a world leader in online audiovisual technology, empowering content creators and digital professionals to transform their ideas into immersive, impactful experiences. From award-winning cameras, microphones, and lighting to control surfaces, capture cards, and studio mounts, Elgato sets industry benchmarks that shape the status quo of digital storytelling. Backed by parent company CORSAIR (Nasdaq: CRSR), the brand leverages a strong global distribution network and consistent product innovation to deliver sustained growth. A trusted name in a rapidly expanding market, Elgato drives value for both creators and investors through its commitment to excellence and forward-thinking strategy. About Corsair Gaming Corsair (Nasdaq: CRSR) is a leading global developer and manufacturer of high-performance products and technology for gamers, content creators, and PC enthusiasts. From award-winning PC components and peripherals to premium streaming equipment and smart ambient lighting, Corsair delivers a full ecosystem of products that work together to enable everyone, from casual gamers to committed professionals, to perform at their very best. Corsair also sells products under its Fanatec brand, the leading end-to-end premium Sim Racing product line; Elgato brand, which provides premium studio equipment and accessories for content creators; SCUF Gaming brand, which builds custom-designed controllers for competitive gamers; Drop, the leading community-driven mechanical keyboard brand; and ORIGIN PC brand, a builder of custom gaming and workstation desktop PCs. Forward-Looking Statements This press release contains express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the refinancing supporting the Company's growth plan and providing it flexibility to act on growth investments. Forward-looking statements are based on our management's beliefs, as well as assumptions made by, and information currently available to them. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected. Factors which may cause actual results to differ materially from current expectations include, but are not limited to: the Company's limited operating history, which makes it difficult to forecast the Company's future results of operations; current macroeconomic conditions, including the impacts of high inflation and risk of recession, on demand for our products, consumer confidence and financial markets generally; changes in trade regulations, policies, and agreements and the imposition of tariffs that affect our products or operations, including potential new tariffs that may be imposed on U.S. imports and our ability to mitigate; the Company's ability to build and maintain the strength of the Company's brand among gaming and streaming enthusiasts and ability to continuously develop and successfully market new products and improvements to existing products; the introduction and success of new third-party high-performance computer hardware, particularly graphics processing units and central processing units as well as sophisticated new video games; fluctuations in operating results; the loss or inability to attract and retain key management; the impacts from geopolitical events and unrest; delays or disruptions at the Company or third-parties' manufacturing and distribution facilities; and the other factors described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ("SEC") and our subsequent filings with the SEC. All forward-looking statements reflect our beliefs and assumptions only as of the date of this press release. We undertake no obligation to update forward-looking statements to reflect future events or circumstances. View source version on Contacts Investor Relations Contact: David Pasqualeir@ 914-337-8801 Media Contact: Timothy Bibatbiba@ 203-428-3222 Error in retrieving data Sign in to access your portfolio Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store